Mauro Di Ianni
Overview
Explore the profile of Mauro Di Ianni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
2032
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liberatore C, Fioritoni F, Natale A, Montanaro G, La Barba G, Passeri C, et al.
EJHaem
. 2023 Nov;
4(4):1152-1156.
PMID: 38024589
The coexistence of chronic myeloid leukemia (CML) and multiple myeloma (MM) is a rare clinical condition. By means of FISH and molecular analysis on both sorted CD138 plasma cells and...
12.
Pennese E, Salutari P, Carriero L, Restuccia F, De Filippis A, De Luca G, et al.
Front Immunol
. 2023 Oct;
14:1272798.
PMID: 37841271
CAR-T therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. Patients who are receiving such therapy are susceptible to an increased incidence of infections due to post-treatment immunosuppression. The need...
13.
Liberatore C, Di Ianni M
Int J Mol Sci
. 2023 Oct;
24(19).
PMID: 37834466
The management of patients with acute myeloid leukemia (AML) relapsed post allogeneic hematopoietic stem cell transplantation (HSCT) remains a clinical challenge. Intensive treatment approaches are limited by severe toxicities in...
14.
Adamo F, Barcelos E, De Falco F, Dorillo E, Rompietti C, Sorcini D, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509279
Background: Chronic lymphocytic leukemia (CLL) is an incurable disorder associated with alterations in several pathways essential for survival and proliferation. Despite the advances made in CLL therapy with the new...
15.
Liberatore C, Perini T, Passeri C, Ferla V, Fioritoni F, Girlando V, et al.
Haematologica
. 2023 Jul;
108(12):3502-3505.
PMID: 37439346
No abstract available.
16.
Guardalupi F, Sorrentino C, Corradi G, Giancola R, Baldoni S, Ulbar F, et al.
Leukemia
. 2023 Jun;
37(7):1572-1575.
PMID: 37286785
No abstract available.
17.
Fatigue as Mediator Factor in PTSD-Symptoms after Allogeneic Hematopoietic Stem Cell Transplantation
Di Francesco G, Cieri F, Esposito R, Sciarra P, Ballarini V, Di Ianni M, et al.
J Clin Med
. 2023 Apr;
12(8).
PMID: 37109093
Background: Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is a valid treatment for hematological oncological or metabolic diseases. Despite its therapeutic efficacy, it is an aggressive treatment that impacts negatively on...
18.
Pagotto S, Simeone P, Brocco D, Catitti G, De Bellis D, Vespa S, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831396
Extracellular vesicles (EVs) are a heterogenous population of plasma membrane-surrounded particles that are released in the extracellular milieu by almost all types of living cells. EVs are key players in...
19.
Santoro N, Mooyaart J, Devillier R, Koc Y, Vydra J, Castagna L, et al.
Bone Marrow Transplant
. 2022 Dec;
58(1):119-120.
PMID: 36517566
No abstract available.
20.
Santoro N, Mooyaart J, Devillier R, Koc Y, Vydra J, Castagna L, et al.
Bone Marrow Transplant
. 2022 Oct;
58(1):54-60.
PMID: 36216975
Donor lymphocyte infusion (DLI) is a treatment option to prevent or treat relapse after allogeneic hematopoietic cell transplantation (HCT). We here report data for 173 patients who received one or...